Biomarkers of Liver Fibrosis


Chronic liver injury leads to the accumulation of proteins in the liver that form dense scars. Liver scar formation is typically a slow process that leads to major organ damage and loss of function over the course of many years. During scar formation the extracellular matrix in the liver changes. The type and quantity of extracellular collagen and other proteins change during tissue remodeling. Some of these changes can be detected by analyzing factors present in blood. Because of the lengthy time course, changes in the rate of liver scar formation and regression are very difficult measure; however, accurate measurements are needed in order to conduct trials of interventions aimed at preventing scar formation and/or promotion scar regression. Current methods have sub-optimal specificity and selectivity. The long term objective of the study is to identify serum proteins that can be used to accurately estimate rates of liver fibrosis progression and regression. The project focusses on a novel methodology that uses stable isotope labeling with deuterated water, D2O, to tag newly-synthesized proteins. Mass spectroscopy is used to identify individual proteins and to quantify the ratio of labeled protein to total protein. This ratio provides information about the rate of synthesis of the protein of interest. This method will be applied to specimens from patients with hepatitis C virus (HCV) infection who are about to begin HCV treatment. Treatment is known to reduce liver inflammation and collagen content.

Study Start Date

June 2015

Estimated Completion Date

June 2018


No interventions cited


  • Internal Medicine: Gastroenterology
  • Infectious Disease: Hepatitis
  • Gastroenterology: Hepatology
  • Family Medicine: Gastroenterology

MeSH Terms

  • Hepatitis C

Study ID

Mount Sinai School of Medicine -- Temp 100



Trial ID


Study Type


Trial Phase


Enrollment Quota



Mount Sinai School of Medicine

Inclusion Criteria

  • Adult (18 years of age or older)
  • Positive test for HCV RNA
  • Planning to initiate treatment for HCV in the near future
  • Not diagnosed with any additional liver diseases, such as autoimmune hepatitis, hepatitis B, alcoholic liver disease, or HIV
  • Able to travel to Mount Sinai
  • Must understand and speak English
  • Willing to sign informed consent and participate

Exclusion Criteria

  • Pregnancy
  • Incarcerated Person




18 Years and older

Accepts Healthy Volunteers


Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Icahn School of Medicine at Mount Sinai - New York, New York 46.8 miles Meena Bansal MD 212-659-9519 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.